Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by A. R. Brazzale
Free Fatty Acid Kinetics During Long-Term Treatment With Pioglitazone Added to Sulfonylurea or Metformin in Type 2 Diabetes
Journal of Internal Medicine
Internal Medicine
Related publications
54-Or: Oral Semaglutide vs. Empagliflozin Added on to Metformin Monotherapy in Uncontrolled Type 2 Diabetes: PIONEER 2
Diabetes
Internal Medicine
Endocrinology
Metabolism
Diabetes
Comparison of Effect of Pioglitazone With Metformin or Sulfonylurea (Monotherapy and Combination Therapy) on Postload Glycemia and Composite Insulin Sensitivity Index During an Oral Glucose Tolerance Test in Patients With Type 2 Diabetes
Diabetes Care
Internal Medicine
Endocrinology
Advanced
Metabolism
Specialized Nursing
Diabetes
Systemic and Regional Free Fatty Acid Metabolism in Type 2 Diabetes
American Journal of Physiology - Endocrinology and Metabolism
Endocrinology
Physiology
Metabolism
Diabetes
Glycemic Control With Diet, Sulfonylurea, Metformin, or Insulin in Patients With Type 2 Diabetes MellitusProgressive Requirement for Multiple Therapies (UKPDS 49)
JAMA - Journal of the American Medical Association
Medicine
Comparison of Antioxidative Effect of Metformin and Combination of Metformin-Sulfonylurea in Type 2 Diabetes Mellitus Patients
Journal of Young Pharmacists
Toxicology
Pharmaceutics
Pharmacology
Preventing, Delaying, or Masking Type 2 Diabetes With Metformin in the Diabetes Prevention Program?
Diabetes Care
Internal Medicine
Endocrinology
Advanced
Metabolism
Specialized Nursing
Diabetes
Cost-Effectiveness Analysis of Linagliptin Versus Sulfonylurea as Add-On Treatment to Metformin for the Treatment of Diabetes Mellitus Type 2 Patients in Indonesia
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
The Cost-Effectiveness of Alogliptin Versus Sulfonylurea as Add-On Therapy to Metformin in Patients With Uncontrolled Type 2 Diabetes Mellitus
Diabetes Therapy
Internal Medicine
Endocrinology
Metabolism
Diabetes
Metformin as First-Line Treatment for Type 2 Diabetes
The Lancet
Medicine